Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse.
Tampellini M, Berruti A, Gorzegno G, Bitossi R, Bottini A, Durando A, De Matteis A, Farris A, Donadio M, De Fabiani E, Manzin E, Arese P, Sarobba MG, Castiglione F, Moro G, Bonazzi G, Nuzzo F, Massobrio M, Dogliotti L. Tampellini M, et al. Among authors: de matteis a, de fabiani e. Tumour Biol. 2001 Nov-Dec;22(6):367-73. doi: 10.1159/000050639. Tumour Biol. 2001. PMID: 11786730
Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients.
Tampellini M, Berruti A, Bitossi R, Gorzegno G, Alabiso I, Bottini A, Farris A, Donadio M, Sarobba MG, Manzin E, Durando A, Defabiani E, De Matteis A, Ardine M, Castiglione F, Danese S, Bertone E, Alabiso O, Massobrio M, Dogliotti L. Tampellini M, et al. Breast Cancer Res Treat. 2006 Aug;98(3):241-8. doi: 10.1007/s10549-005-9155-y. Epub 2006 May 3. Breast Cancer Res Treat. 2006. PMID: 16670941
Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design.
Berruti A, Bitossi R, Gorzegno G, Bottini A, Alquati P, De Matteis A, Nuzzo F, Giardina G, Danese S, De Lena M, Lorusso V, Farris A, Sarobba MG, DeFabiani E, Bonazzi G, Castiglione F, Bumma C, Moro G, Bruzzi P, Dogliotti L; Epirubicin-Lonidamine Group, Orbassano, Torino, Italy. Berruti A, et al. J Clin Oncol. 2002 Oct 15;20(20):4150-9. doi: 10.1200/JCO.2002.08.012. J Clin Oncol. 2002. PMID: 12377958 Clinical Trial.
Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretreated metastatic breast cancer patients. A multicenter phase II trial.
Donadio M, Manzin E, Berruti A, Bottini A, Gorzegno G, Danese S, DeFabiani E, Sarobba MG, Lorusso V, Castiglione F, Moro G, Bertetto O, Bumma C, Dogliotti L. Donadio M, et al. Cancer Chemother Pharmacol. 2001 May;47(5):391-6. doi: 10.1007/s002800000247. Cancer Chemother Pharmacol. 2001. PMID: 11391853 Clinical Trial.
Benign breast disease. An update.
Sismondi P, Giai M, Defabiani E, Biglia N. Sismondi P, et al. Clin Exp Obstet Gynecol. 1990;17(2):53-116. Clin Exp Obstet Gynecol. 1990. PMID: 2265480 Review. No abstract available.
[Secondary effects of adjuvant therapy].
Giai M, De Fabiani E, Lamberto A, Cortese P, Giardina G. Giai M, et al. Among authors: de fabiani e. Minerva Ginecol. 1985 Jun;37(6):319-28. Minerva Ginecol. 1985. PMID: 3162112 Italian. No abstract available.
82 results